Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S565000
Reexamination Certificate
active
10854689
ABSTRACT:
Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formulawhereinm is 0, 1, 2, 3 or 4;each X is independently selected from the group consisting of hydrogen, halo, cyano, nitro, OCF3, hydroxy, amino, carboxyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, haloalkyl, alkoxy, alkoxycarbonylalkyl, hydroxycarbonylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkylalkyl, R1O, R1R2N, R1OCO, R1CO, R1R2NCO, R1R2NCONR2a, R1OCONR2a, R1CONR2a, R1S, R1SO, R1SO2, R1R2NSO2, R1R2NSO2NR2a, and R1SO2NR2a;R1is alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl;R2and R2aare the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl;n is 1, 2, or 3;W is O or H,R3;R3is hydrogen or hydroxyl;Ar is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group;Q is hydrogen, F, or hydroxyl.In addition, a method for using these compounds to treat diseases associated with abnormal or mineral homeostasis is also provided.
REFERENCES:
patent: 4411890 (1983-10-01), Momany
patent: 4616017 (1986-10-01), Baldwin et al.
patent: 5688938 (1997-11-01), Brown et al.
patent: 5763569 (1998-06-01), Brown et al.
patent: 6022894 (2000-02-01), Del Mar et al.
patent: 6031003 (2000-02-01), Nemeth et al.
patent: 6211244 (2001-04-01), Van Wagenen et al.
patent: 7053212 (2006-05-01), Cameron et al.
patent: 7105537 (2006-09-01), Gavai et al.
patent: 0342613 (1992-11-01), None
patent: 0449011 (1997-10-01), None
patent: WO89/07110 (1989-08-01), None
patent: WO89/07111 (1989-08-01), None
patent: WO93/04081 (1993-03-01), None
patent: WO94/18959 (1994-09-01), None
patent: WO97/37967 (1997-10-01), None
patent: WO98/45255 (1998-10-01), None
patent: WO99/51241 (1999-10-01), None
patent: WO99/51569 (1999-10-01), None
patent: WO 00/45816 (2000-08-01), None
patent: WO 01/08673 (2001-02-01), None
patent: WO 2005/115975 (2005-12-01), None
Bodkin et al. “Preparation of substituted 1-phenoxy . . . ” Ca 135:210941 (2001).
Yang et al. “Discovery and structure activity . . . ” Bioorg. Med. chem. Lett. v.15, pp. 1225-1228 (2005).
Arndt, D., “Mangan-Verbindungen als Oxidationsmittel in der organischen Chemie”, Methoden der Organischen Chemie (Houben-Weyl), Fourth Edition, vol. 4, Part 1b, Georg Thieme Verlag, Stuttgart, publ., Müller, E., ed., pp. 466-672 (1975).
Betts, M.J. et al., “‘Hidden’ axial chirality as a stereodirecting element in reactions involving enol(ate) intermediates. Part 2. Cyclisation reactions of methyl (4R)-3-(2-diazo-3-oxobutanoyl)-1,1-dioxo-1λ6, 3- (and 1-oxo-1λ4, 3-) thiazolidine-4-carboxylates”, J. Chem. Soc., Perkin Trans. 1, pp.
Brown, E.M. et al., “Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid”, Nature, vol. 366, pp. 575-580 (1993).
Bundgaard, H. Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Cagniant, P. et al., “No. 50. Sur la synthése de quelques amines arylaiphatiques dérivées du β- méthyl-naphtaléne”, Bull. Soc. Chim. Fr., pp. 349-353 (1943).
Edwards, J.P. et al., “Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H- pyrano[3,2-g]quinolin-2-one”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1003-1008 (1999).
Florvall, L. et al., “Selective Monoamine Oxidase Inhibitors. 3. Cyclic Compounds Related to 4-Aminophenethylamine. Preparation and Neuron-Selective Action of Some 5-(2-Aminoethyl)-2,3- dihydroindoles”, J. Med. Chem., vol. 29, No. 8, pp. 1406-1412 (1986).
Gowen, M. et al., “Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats”, The Journal of Clinical Investigation, vol. 105, No. 11, pp. 1595-1604 (2000).
Greene, T.W. et al., Protecting Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ. (1999) (table of contents).
Greenstein, J.P. et al., Chemistry of the Amino Acids, vol. 3, Robert E. Krieger Publishing Company, Inc., publ., pp. v-xiii (table of contents) (1984).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)”, J. Med. Chem., vol. 42, pp. 210-212 (1999).
Hudlický, M., Oxidations in Organic Chemistry: ACS Monograph 186, American Chemical Society, publ., pp. ix-xiii (table of contents) (1990).
Larock, R.C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., publ., pp. xiii-xxviii (table of contents) (1989).
Lee, D.G., Chapter 11: “Phase Transfer Assisted Permanganate Oxidations”, Oxidation in Organic Chemistry, Part D, Academic Press, publ., Trahanovsky, W.S., ed., pp. 147-204 (1982).
Moed, H.D. et al., “Synthesis ofβ-phenyl-ethylamine Derivaties. III) Bronchodilators”, Recl. Trav. Chim. Pays-Bas, vol. 74, pp. 919-936 (1955).
Neer, R.M. et al., “Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis”, The New England Journal of Medicine, vol. 344, No. 19, pp. 1434-1441 (2001).
Nichols, D.E. et al., “Effects of Certain Hallucinogenic Amphetamine Analogues on the Release of [3H]Serotonin from Rat Brain Synaptosomes”, J. Med. Chem., vol. 25, No. 5, pp. 530-535 (1982).
Norris, R.K. et al., “Kinetics and Stereochemistry of Elimination of Nitrous Acid from 1-p- Nitrophenyl-2-nitroethyl Derivatives”, Aust. J. Chem., vol. 39, pp. 281-294 (1986).
Stewart, R., Chapter 1: “Oxidation by Permanganate”, Oxidation in Organic Chemistry, Part A, Academic Press, publ., Wiberg, K.B., ed., pp. 1-68 (1965).
Wermuth, C.G. et al., Chapter 31: “Designing Prodrugs and Biprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996).
Whitfield, J.F. et al., “Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis”, Treat. Endocrinol., vol. 1, No. 3, pp. 175-190 (2002).
Zaragoza, F. et al., “(Cyanomethyl)trialkylphosphonium lodides: Efficient Reagents for the Intermolecular Alykylation of Amines with Alcohols in Solution and on Solid Phase”, J. Org. Chem., vol. 66, No. 7, pp. 2518-2521 (2001).
Dickson John K.
Lawrence R. Michael
Roberge Jacques Y.
Rotella David P.
Yang Wu
Bristol--Myers Squibb Company
Chang Celia
O'Brien Maureen P.
LandOfFree
Substituted piperidines and pyrrolidines as calcium sensing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperidines and pyrrolidines as calcium sensing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidines and pyrrolidines as calcium sensing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767630